27

FEB

25

The Drug Cell : A new french alliance to redefine cell therapies

The French company “The Drug Cell” (TDC) has just been officially created, marking a decisive step forward for the European cell therapy sector.

Institute for Stem cell Therapy and Exploration of Monogenic diseases

In 2025, advancing research on rare and ultra-rare monogenic diseases requires the mobilization of significant human and technological resources. Within I-Stem, we are all mobilized around this common objective.

80

Between scientists and support functions, 80 people currently work at I-Stem.

Teams at the service of ambitious therapeutic objectives

Reasearch
teams

I-Stem brings together within its research teams the expertise and know-how of researchers, teacher-researchers, engineers and technicians. Retinopathies, genodermatoses, Limb-girdle muscular dystrophies, neuromuscular diseases & Myelinated fibers are part of our main scientific themes.

Triails
clinics

Clinical trials are a crucial step in the development of treatments for any pathology. I-Stem is the sponsor of several trials and supports others through partnerships.

stemCARE
Technology plateform

Excellent research requires state-of-the-art equipment. I-Stem is equipped with technological platforms allowing its research teams to optimize their fundamental, pre-clinical and clinical research projects.

News

  • News
  • Publications
Press release

27 February 2025

The French company “The Drug Cell” (TDC) has just been officially created, marking a decisive step forward for the European cell therapy sector.

Press release

16 January 2025

For the 2024 edition of its call for proposals, GIS IBiSA has defined several priority themes, including pluripotent stem cells.
Among the structures specialized in this field, the stemCARE technology platform has been selected for labeling.

Event

20 September 2024

Pr HÉNON Philippe will present a seminar at I-Stem on September 26, 2024, entitled: CD34+ cells and Very Small Embryonic-Like stem cells (VSELs) : Clinical applications in cardiology.

CACNA1S gene variants are associated with congenital myopathies (CMyo) with triad dysfunction (triadopathies), malignant hyperthermia susceptibility, hypokalemic periodic paralysis and thyrotoxic periodic paralysis. Here, we generated three iPSC lines derived from patients with CMyo linked to bot...

Motoneuron

21 May 2025

Amyotrophic lateral sclerosis (ALS) is a multifactorial motor neuron (MN) disease, characterized by several cellular dysfunctions, many of which are shared by different neurodegenerative diseases. Here, we investigated whether a stressful lifestyle might exacerbate the altered mechanisms and affe...

I-Stem is a member of the Institute of Biotherapies for Rare Diseases created by the AFM - Telethon